AI
Sophia Panagiotopoulou makes it look so straightforward. Engineer T cells, sequence RNA, crunch the numbers, and let AI spit out targets. Boom, done. But behind all of this is an intense, computationally ferocious machine, one that required 968,100 CPU hours (it's close enough to a million to
Drug Discovery
At the heart of drug discovery there’s a paradox both frustrating and familiar to anyone steeped in pharmaceutical research: the vast oceans of preclinical data that flood in from assays, structural analyses, and early molecular testing. All of this contrasts starkly with the scarce trickle of clinical data that
AI
If you want to see what an antibody language model trained only on humans can actually do, GLIMPSE-1 is your proof. No mouse scaffolds or synthetic libraries. And no structural hallucinations either. Just native human sequence data, paired heavy-light chains, and a model trained to learn the logic evolution already
News
AstraZeneca is placing a $110 million direct bet on CSPC Pharmaceuticals AI platform in Shijiazhuang. It’s not about factories or sales, it’s about code. CSPC, which few in the West have heard of and which has only a small trace on the web, will power discovery with a
Protein Design
Most of what passes for protein design these days is better described as substitution. You take a known backbone, swap in plausible residues based on energy or evolutionary alignment, and run it through simulation until the numbers settle into something stable. It works, in a way, but it’s more